RecruitingNCT04178408

IBD Registry in a Sub-Saharan African Population

Registry to Study the Incidence, Phenotype, Risk Factors and Clinical Course of Inflammatory Bowel Disease in Zimbabwe

Sponsor

University of Zimbabwe

Enrollment

100 participants

Start Date

Jan 2, 2021

Study Type

OBSERVATIONAL

Conditions

Inflammatory Bowel Diseases Crohn Disease Ulcerative Colitis

Summary

The investigators intend to establish a prospective registry of patients diagnosed with inflammatory bowel disease at Parirenyatwa hospital in Harare, Zimbabwe. The study will periodically collect data on disease phenotype, disease course, and clinical management, and will biobank stool specimens and germline DNA. One relative, and an individual from the same neighbourhood will be also be recruited for a nested case-control study into risk factors of inflammatory bowel disease in this population.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is building a medical registry of people with inflammatory bowel disease (IBD — including Crohn's disease and ulcerative colitis) in Sub-Saharan Africa, to better understand how the disease presents, progresses, and is treated in this population. **You may be eligible if...** - You have a confirmed diagnosis of IBD (Crohn's disease, ulcerative colitis, or similar) - Your symptoms began at least 3 months ago - OR you are a healthy person (sibling, cousin, or neighbor of someone with IBD) willing to participate as a comparison group **You may NOT be eligible if...** - You are a healthy control with symptoms that suggest IBD (unexplained diarrhea, weight loss, abdominal pain) - You are under 18 (controls only; cases of any age may be included) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.